Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Benyunes
M C
MC
Division of Oncology, University of Washington, Seattle.
Thompson
J A
JA
York
A
A
Buckner
C D
CD
Fefer
A
A
D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D014182:Transplantation, Autologous
D007376:Interleukin-2